Matches in Nanopublications for { ?s ?p "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP980313.RAbkA9ieX1kgXI_HxZOrz_fUnrG28YPvvghMqz-ypMHFU130_provenance.
- NP980314.RAcp5Lw5JgqGUFKqdBVQegLu9otbD3Kz8RgABofFWeVXs130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP980314.RAcp5Lw5JgqGUFKqdBVQegLu9otbD3Kz8RgABofFWeVXs130_provenance.
- NP645891.RAGQbF1LZ_p7qR3EVcmv_dchQIH3sYim7Dw0D4LnYnpVQ130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645891.RAGQbF1LZ_p7qR3EVcmv_dchQIH3sYim7Dw0D4LnYnpVQ130_provenance.
- NP645993.RAESu7lQLW9GZx0pZQqqwvtDuB1CTp0gJklRrmeialdc0130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645993.RAESu7lQLW9GZx0pZQqqwvtDuB1CTp0gJklRrmeialdc0130_provenance.
- NP645879.RA0ICqDcN6U0Yzrhbzco42NRgS_iN4mJgZHtwsBx75f-0130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645879.RA0ICqDcN6U0Yzrhbzco42NRgS_iN4mJgZHtwsBx75f-0130_provenance.
- NP980310.RAJ4wgrkX6wyloPPij65Z8N29EuoglXyRl_VJt0Xlo7LM130_assertion description "[This study evaluated the preclinical activity of selumetinib (AZD6244, ARRY-142866), an inhibitor of the mitogen-activated protein kinase kinase (MAPKK or MEK1/2) in 6 nasopharyngeal cancer (NPC) cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP980310.RAJ4wgrkX6wyloPPij65Z8N29EuoglXyRl_VJt0Xlo7LM130_provenance.